Next Article in Journal
Genomic Analysis of Historical Cases with Positive Newborn Screens for Short-Chain Acyl-CoA Dehydrogenase Deficiency Shows That a Validated Second-Tier Biochemical Test Can Replace Future Sequencing
Next Article in Special Issue
It All Depends What You Count—The Importance of Definitions in Evaluation of CF Screening Performance
Previous Article in Journal
The Importance of Succinylacetone: Tyrosinemia Type I Presenting with Hyperinsulinism and Multiorgan Failure Following Normal Newborn Screening
Previous Article in Special Issue
Pancreatitis-Associated Protein in Neonatal Screening for Cystic Fibrosis: Strengths and Weaknesses
Open AccessReview

Constructing a Bioethical Framework to Evaluate and Optimise Newborn Bloodspot Screening for Cystic Fibrosis

1
Department of Women’s and Children’s Health, University of Liverpool, Liverpool L12 2AP, UK
2
Institute of Population Health, University of Liverpool, Liverpool L69 3GL, UK
3
Division of Psychology & Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9PL, UK
*
Author to whom correspondence should be addressed.
Int. J. Neonatal Screen. 2020, 6(2), 40; https://doi.org/10.3390/ijns6020040
Received: 13 March 2020 / Revised: 1 May 2020 / Accepted: 4 May 2020 / Published: 26 May 2020
(This article belongs to the Special Issue Newborn Screening for Cystic Fibrosis)
Newborn bloodspot screening for cystic fibrosis is a valid public health strategy for populations with a high incidence of this inherited condition. There are a wide variety of approaches to screening and in this paper, we propose that a bioethical framework is required to determine the most appropriate screening protocol for a population. This framework depends on the detailed evaluation of the ethical consequences of all screening outcomes and placing these in the context of the genetic profile of the population screened, the geography of the region and the healthcare resources available. View Full-Text
Keywords: cystic fibrosis; newborn bloodspot screening; cystic fibrosis screen positive; inconclusive diagnosis (CFSPID); bioethics cystic fibrosis; newborn bloodspot screening; cystic fibrosis screen positive; inconclusive diagnosis (CFSPID); bioethics
Show Figures

Figure 1

MDPI and ACS Style

Armstrong, R.E.; Frith, L.; Ulph, F.M.; Southern, K.W. Constructing a Bioethical Framework to Evaluate and Optimise Newborn Bloodspot Screening for Cystic Fibrosis. Int. J. Neonatal Screen. 2020, 6, 40.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop